Market Place
Sourcing Support
Astrazeneca Breast Cancer Drug Fails FDA Advisory Committee
01 May 2026 //
BIOSPACE
FDA Panel Rejects AstraZeneca Oral SERD Over Insufficient OS Data
30 Apr 2026 //
FIRSTWORD PHARMA
FDA, AstraZeneca prep for oncology adcomm
29 Apr 2026 //
ENDPOINTS
Astra`s Tozorakimab Delivers Reduction in Lung Disease Flare-ups
20 Apr 2026 //
REUTERS
Astrazeneca`s IL-33 To Broaden Biologics Reach In COPD
16 Apr 2026 //
FIRSTWORD PHARMA
IMFINZI + IMJUDO Improves PFS in Early Liver Cancer
02 Apr 2026 //
BUSINESSWIRE
Another Astrazeneca Emerald Glimmers In Liver Cancer
02 Apr 2026 //
FIERCE PHARMA
Astrazeneca In Vivo Data Shows Potential, Despite Patient Death
28 Mar 2026 //
FIERCE BIOTECH
AstraZeneca`s COPD Hit Revives Class Rocked by Flops
27 Mar 2026 //
FIERCE BIOTECH
AstraZeneca Drug Reduces COPD Flare ups in Late-stage Trials
27 Mar 2026 //
REUTERS
Amani Therapeutics Closes $25 Million Series A to Advance AM-01
23 Mar 2026 //
PHARMIWEB
AZ To Build Cell Therapy Supply Hub, R&D Center In Shanghai
20 Mar 2026 //
PRESS RELEASE
AstraZeneca Pharma India receives CDSCO approval for Durvalumab
17 Mar 2026 //
EXPRESSPHARMA
Astrazeneca Drugs Face FDA Cancer Advisory Panel After 9 Months
09 Mar 2026 //
BIOSPACE
Daiichi Sankyo, AZ`s Enhertu wins US priority review
09 Mar 2026 //
FIERCE PHARMA
FDA to end 9-month adcomm hiatus with review of AZ`s cancer drugs
06 Mar 2026 //
FIERCE PHARMA
AIM ImmunoTech Signs Ampligen Phase 3 Trial Deal
02 Mar 2026 //
GLOBENEWSWIRE
FDA Approves Venclexta, Acalabrutinib For Untreated CLL Leukemia
23 Feb 2026 //
PRESS RELEASE
BREZTRI Shows Positive Phase III Results In Uncontrolled Asthma
13 Feb 2026 //
BUSINESSWIRE
Astrazeneca Relaxed About Relaxin Drug`s Poor Efficacy In Ph. 2
10 Feb 2026 //
FIERCE BIOTECH
Astrazeneca`s Oral GLP-1 Scored Phase 2 Wins, But No Data Yet
10 Feb 2026 //
FIERCE BIOTECH
AstraZeneca Gets CDSCO Nod for Imfinzi in New Indication
10 Feb 2026 //
ECONOMICTIMES
The Biggest Potential Drug Launches Of 2026
06 Feb 2026 //
FIERCE PHARMA
AstraZeneca Wins CDSCO Nod for Durvalumab in Gastric Cancer
06 Feb 2026 //
ECONOMICTIMES
AIM Reports Positive Interim Ph2 Data of Ampligen Combo in Cancer
05 Feb 2026 //
GLOBENEWSWIRE
FDA Priority Review for DATROWAY for Metastatic Breast Cancer
03 Feb 2026 //
BUSINESSWIRE
Daiichi Stops Internal Development Of Next-Wave ADC
02 Feb 2026 //
FIERCE BIOTECH
Astrazeneca Vows $15B China Investment To Boost R&D Capabilities
30 Jan 2026 //
FIERCE BIOTECH
Multiply Labs Partners to Automate Cell Therapy Manufacturing
27 Jan 2026 //
BUSINESSWIRE
AstraZeneca keeps UK Research Site on Pause, But Options Open
27 Jan 2026 //
FIERCE BIOTECH
Daiichi Sankyo Navigates Complexity Of Success
26 Jan 2026 //
FIERCE PHARMA
ENHERTU + Pertuzumab EU Filing Validated for HER2+ Breast Cancer
19 Jan 2026 //
BUSINESSWIRE
ENHERTU Plus Pertuzumab EU Type II Variation Validated
19 Jan 2026 //
BUSINESSWIRE
AstraZeneca Acquires China Rights to GPC3 Armored CAR-T Therapy
18 Jan 2026 //
PR NEWSWIRE
AstraZeneca to acquire Modella AI to Speed Oncology Drug Research
13 Jan 2026 //
PRESS RELEASE
Bostongene, Astrazeneca Partner To Advance Oncology Development
06 Jan 2026 //
BUSINESSWIRE
AZ Touts Phase 3 Lupus Win For Subcutaneous Saphnelo
06 Jan 2026 //
FIERCE PHARMA
Astrazeneca`s Ph. 3 Cancer Fail Is Latest Blow To ATR Inhibitors
24 Dec 2025 //
FIERCE BIOTECH
FDA Grants ENHERTU BTD for HER2+ Early Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
FDA OKs ENHERTU Breakthrough Designation for HER2+ Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
EU Validates DATROWAY for First-Line Metastatic Treatment
18 Dec 2025 //
BUSINESSWIRE
Astrazeneca India Granted CDSCO Approval For Datopotamab
18 Dec 2025 //
INDPHARMAPOST
GSK`s Saphnelo EU Approved For Self-Administered Lupus Pen
16 Dec 2025 //
PHARMIWEB
FDA Approves AZ/Daiichi`s Enhertu in 1st-Line Breast Cancer
15 Dec 2025 //
BUSINESSWIRE
FDA Launches Probe Into Safety Of Approved Anti-RSV Antibodies
10 Dec 2025 //
BIOSPACE
DESTINY-Ovarian01—ENHERTU Phase 3 Begins for HER2+Ovarian Cancer
09 Dec 2025 //
BUSINESSWIRE
Pillar Bio, Astrazeneca Expand Liquid Biopsy Access In China
08 Dec 2025 //
PR NEWSWIRE
Neurimmune Expands Collaboration With Astrazeneca On NI009
04 Dec 2025 //
PR NEWSWIRE
AstraZeneca Picks Salesforce Agentforce for Life Sciences
04 Dec 2025 //
BUSINESSWIRE
AstraZeneca`s Record ASH Presence Advances Hematology
04 Dec 2025 //
BUSINESSWIRE
Az`s Imfinzi Bags Perioperative Nod In Early-Stage Stomach Cancer
25 Nov 2025 //
FIERCE PHARMA
Astrazeneca Expands Obesity Pipeline Focusing On Medical Aspects
06 Nov 2025 //
BIOSPACE
Breakthrough Properties Finishes Leasing One Helix To Astrazeneca
04 Nov 2025 //
PR NEWSWIRE
EU Okays Alexion’s Koselugo For Adults With Neurofibromatosis
31 Oct 2025 //
INDPHARMAPOST
Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
30 Oct 2025 //
BUSINESSWIRE
Biogen Seeks To Stand Out In Lupus With New Anti-CD40L Data
28 Oct 2025 //
BIOSPACE
Imfinzi Reduces Death Risk By 32% In High-Risk Bladder Cancer
22 Oct 2025 //
INDPHARMAPOST
CHMP Recommends Saphnelo Self-Admin Approval For Lupus In EU
21 Oct 2025 //
PHARMIWEB
ESMO: The ADC `Rollercoaster` Rides On With Next-Gen Meds
21 Oct 2025 //
FIERCE BIOTECH
AstraZeneca`s Datroway Extends Survival in Breast Cancer
20 Oct 2025 //
REUTERS
